|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Prepaid clinical trial costs | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Non-current prepaid clinical trial costs | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Short-term debt | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued clinical expenses | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Equity | ||||||||||||||||||||
| Common stock, par value of $0.0001; 515,000,000 shares authorized; 13,110,377 and 5,872,865 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity |
Loading...
